American Association for Cancer Research
15357163mct110937-sup-f1_pdf_39k.pdf (39.64 kB)

Supplementary Figure 1 from Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer

Download (39.64 kB)
journal contribution
posted on 2023-04-03, 13:26 authored by Mickey K. Kim, Takuya Osada, William T. Barry, Xiao Yi Yang, Jennifer A. Freedman, Katherine A. Tsamis, Michael Datto, Bryan M. Clary, Timothy Clay, Michael A. Morse, Philip G. Febbo, H. Kim Lyerly, David S. Hsu

PDF file - 39K, Fifty-nine samples from the NCI-60 cell panel were RMA normalized and base on 3D principal components analysis, MCF-7 was ommitted from further analysis.



Despite advances in contemporary chemotherapeutic strategies, long-term survival still remains elusive for patients with metastatic colorectal cancer. A better understanding of the molecular markers of drug sensitivity to match therapy with patient is needed to improve clinical outcomes. In this study, we used in vitro drug sensitivity data from the NCI-60 cell lines together with their Affymetrix microarray data to develop a gene expression signature to predict sensitivity to oxaliplatin. To validate our oxaliplatin sensitivity signature, patient-derived colorectal cancer explants (PDCCE) were developed in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice from resected human colorectal tumors. Analysis of gene expression profiles found similarities between the PDCCEs and their parental human tumors, suggesting their utility to study drug sensitivity in vivo. The oxaliplatin sensitivity signature was then validated in vivo with response data from 14 PDCCEs treated with oxaliplatin and was found to have an accuracy of 92.9% (sensitivity = 87.5%; specificity = 100%). Our findings suggest that PDCCEs can be a novel source to study drug sensitivity in colorectal cancer. Furthermore, genomic-based analysis has the potential to be incorporated into future strategies to optimize individual therapy for patients with metastatic colorectal cancer. Mol Cancer Ther; 11(7); 1500–9. ©2012 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager